Get the Stockscreener App
143.58
0.53%
-0.76
Pre-market:
144.27
0.69
+0.48%
Novartis Ag Adr stock is traded at $143.58, with a volume of 1.83M.
It is down -0.53% in the last 24 hours and up +5.53% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$144.34
Open:
$144
24h Volume:
1.83M
Relative Volume:
1.12
Market Cap:
$275.50B
Revenue:
$54.45B
Net Income/Loss:
$14.42B
P/E Ratio:
19.58
EPS:
7.333
Net Cash Flow:
$17.15B
1W Performance:
+1.39%
1M Performance:
+5.53%
6M Performance:
+25.67%
1Y Performance:
+47.22%
1-Day Range:
$142.82
$144.85
1-Week Range:
$142.26
$146.35
52-Week Range:
$97.72
$146.35
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
143.58 | 276.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,041.29 | 929.39B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.21 | 526.82B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.04 | 378.84B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
109.45 | 270.12B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Novartis ADR: Defensive Giant Tests Investor Patience As Rally Cools - AD HOC NEWS
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - Chartmill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Finviz
The Truth About Novartis AG (ADR): Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends - GlobeNewswire Inc.
Is Novartis AG Gaining or Losing Market Support? - Sahm
3 Dividend Stocks to Buy in 2026 and Hold Forever - Finviz
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
New Investors: 3 Stocks to Build Your Portfolio Around in 2026 - Finviz
The Truth About Novartis AG (ADR): Is Wall Street’s Quiet Giant Your Next Power Play? - AD HOC NEWS
The Truth About Novartis AG: Is This Pharma Giant a Silent Stock Cheat Code? - AD HOC NEWS
Novartis AG (ADR): Quiet Confidence Or Complacency? A Deep Look At NVS After A Steady Climb - AD HOC NEWS
7 Newly Overvalued Stocks this Week - Morningstar
EBITDA per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
NVS Price History for Novartis Ag ADR Stock - Barchart.com
2 Top Stocks to Buy and Hold for the Long Term - Finviz
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts - Sahm
Pharma's $370B Bet on America: The ETF Plays for 2026 - Barchart.com
White House Readies Drug Price Deals With AbbVie, Novartis, Roche - Sahm
Novartis, Roche to reach drug pricing deal with White HouseBloomberg - Investing.com
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 - Finviz
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey
Novartis (NVS) enters $1.7 billion development deal, says report - MSN
Price Over Earnings Overview: Novartis - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm
Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):